InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,174.00
(
1.14%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.32
(
0.15%
)
Bitcoin
61,978.55
(
0.28%
)
Post# of 252353
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: DewDiligence post# 124206

Monday, 08/01/2011 8:43:41 AM

Monday, August 01, 2011 8:43:41 AM

Post# of 252353

By contrast, a third group of patients who got Avonex, an older injected treatment from Biogen Idec Inc. (BIIB), had fewer relapses than those who got a placebo in the study.

“Laquinimod is dead, if not regulatorily, then commercially,” said Ori Hershkovitz, a partner at Sphera Funds Management Ltd. in Tel Aviv.



http://www.bloomberg.com/news/2011-08-01/teva-s-oral-multiple-sclerosis-drug-fails-to-meet-goal-of-clinical-trial.html
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up